Reader safety: This is an educational cell-biology guide. Disease examples are used to explain mechanism, not to give diagnosis, treatment or supplement advice.
Wait, What? A Protein Can Gain a Fatty-Acid Tail — and Then Lose It Again
Many proteins need to visit membranes without becoming permanent membrane proteins.
One elegant solution is S-palmitoylation, more broadly called S-acylation: a fatty acyl chain is attached to a cysteine through a reversible thioester bond.
The modification can change where a protein goes, how long it stays there, which partners it meets and how strongly it signals.
protein sequence + reversible lipid attachment = adjustable membrane residency.
The One-Sentence Answer
Learn S-palmitoylation by following an acyl group from acyl-CoA through ZDHHC autoacylation and substrate transfer, then follow the reverse path through depalmitoylases, while testing how the cycle changes localisation, trafficking, stability and signalling rather than treating the lipid mark as a simple on/off switch.
Stage 1: Start With the Chemical Bond
S-palmitoylation attaches a fatty acyl group to the sulfur of a cysteine side chain.
The bond is a thioester. That matters because thioesters are chemically reversible under cellular conditions.
This makes S-palmitoylation fundamentally different from many irreversible lipid modifications.
Stage 2: “Palmitoylation” Is Often Shorthand for S-Acylation
Palmitate is common, but not every modified cysteine necessarily carries exactly the same fatty acyl chain.
So the professional term S-acylation is often more precise.
The useful beginner rule is:
S-palmitoylation is a common reversible cysteine lipidation, but the acyl identity can vary.
Stage 3: Lipidation Changes Membrane Affinity
A soluble protein surface is mostly exposed to water.
Adding a long hydrophobic acyl chain creates a membrane-seeking feature.
That can:
- increase membrane binding;
- stabilise a protein in a membrane microdomain;
- change transport between Golgi, endosomes and plasma membrane;
- alter access to partners or substrates.
Stage 4: One Lipid Is Often Not Enough
Many palmitoylated proteins use dual targeting.
A second signal may be:
- prenylation;
- myristoylation;
- a transmembrane helix;
- a polybasic region;
- a partner-binding domain.
The result is combinatorial localisation rather than one mark doing all the work.
Stage 5: ZDHHC Enzymes Write the Modification
In mammals, a family of membrane proteins containing a conserved DHHC motif catalyses most protein S-acylation.
They are commonly called ZDHHC protein acyltransferases.
The family contains multiple enzymes with overlapping but non-identical substrate preferences and organelle distributions.
Stage 6: The Enzyme First Acylates Itself
ZDHHC catalysis generally proceeds in two broad steps.
First:
acyl-CoA → ZDHHC acyl-enzyme intermediate.
The catalytic cysteine in the DHHC motif becomes transiently acylated.
This is autoacylation.
Stage 7: Then the Acyl Group Moves to the Substrate
Second:
acylated ZDHHC + substrate cysteine → S-acylated substrate + regenerated enzyme.
The enzyme is therefore not merely a scaffold. It passes through a covalent catalytic intermediate.
Stage 8: Substrate Selection Is More Than a Short Consensus Sequence
There is no universal sequence motif that guarantees palmitoylation.
Specificity can depend on:
- local cysteine environment;
- membrane proximity;
- protein conformation;
- accessory proteins;
- the ZDHHC cytosolic domains;
- where enzyme and substrate meet.
Sequence prediction is therefore only a hypothesis generator.
Stage 9: ZDHHC Location Helps Create Substrate Fate
Many ZDHHC enzymes localise to the ER, Golgi, endosomes or plasma membrane.
If a substrate meets its writer in the Golgi, palmitoylation can promote onward trafficking to another membrane.
Spatial enzyme distribution becomes part of the modification code.
Stage 10: Depalmitoylases Reverse the Mark
The thioester can be hydrolysed by several enzyme families.
Important examples include:
- APT1 and APT2;
- ABHD17 family proteins;
- PPT1 in lysosomal pathways;
- other context-dependent serine hydrolases.
There is not one universal eraser for every substrate.
Stage 11: Reversibility Creates a Trafficking Cycle
For proteins such as Ras-family signalling proteins, palmitoylation and depalmitoylation can support repeated movement between intracellular membranes and the plasma membrane.
The mark is not only “present” or “absent”.
The important variable is often turnover rate.
Stage 12: Membrane Residency Is a Dynamic Quantity
Imagine two proteins with the same average percentage palmitoylated.
One cycles rapidly on and off membranes. The other turns over slowly.
The snapshot looks similar, but the trafficking behaviour can be completely different.
This is why kinetics matters.
Stage 13: Ras Shows How Lipid Cycling Controls Signalling Geography
Some Ras isoforms use prenylation plus reversible palmitoylation.
Prenylation gives a persistent hydrophobic anchor; palmitoylation strengthens and redirects membrane association.
Depalmitoylation can release the protein from one membrane environment so it can be redistributed.
Signalling output therefore depends partly on where Ras resides, not only whether Ras exists.
Stage 14: PSD-95 Shows the Same Principle in Neurons
PSD-95 is a synaptic scaffold whose palmitoylation contributes to membrane targeting and organisation of postsynaptic protein complexes.
A reversible lipid mark can therefore alter the architecture of a signalling platform.
Stage 15: Membrane Proteins Can Be Palmitoylated Too
A transmembrane helix already anchors a protein.
Why add another lipid?
Because palmitoylation can still change:
- membrane-domain preference;
- local conformation;
- protein–protein interactions;
- endocytosis;
- stability.
Lipidation is not synonymous with “anchor a soluble protein”.
Stage 16: ZDHHC Enzymes Can Regulate One Another
Some ZDHHC proteins are themselves palmitoylated on regulatory cysteines outside the catalytic site.
This can change interactions or localisation.
The writer network can therefore contain writer-on-writer regulation.
Stage 17: Palmitoylation Can Change Protein Stability
A lipid modification can protect a protein from degradation, expose it to degradation, or alter trafficking into a compartment where turnover differs.
So:
palmitoylation level ≠ protein abundance, but palmitoylation can influence abundance.
Stage 18: Palmitoylation Can Change Protein Conformation
The acyl chain can alter how a nearby peptide region sits against a membrane.
That can change accessibility of interaction surfaces or regulatory sites.
The modification therefore has both a local chemical effect and a spatial localisation effect.
Stage 19: The Acyl Donor Links Lipid Metabolism to Signalling
ZDHHC enzymes use fatty acyl-CoA molecules.
That creates a bridge between cellular lipid metabolism and protein regulation.
But it is too simple to say that more palmitate automatically means more palmitoylation.
Enzyme activity, substrate access, compartmentation and deacylation all matter.
Stage 20: The 2026 Evidence Base Reinforces the Dynamic Model
Recent reviews in 2026 continue to emphasise S-palmitoylation as a reversible regulator of localisation, trafficking, signalling and protein stability, with ZDHHC writers opposed by several depalmitoylase families.
The field is moving from cataloguing modified proteins toward resolving:
- writer–substrate specificity;
- site occupancy;
- turnover;
- subcellular geography;
- causal phenotype.
Stage 21: Acyl-Biotin Exchange Detects Thioester-Linked Cysteines
One classic strategy blocks free thiols, cleaves thioester-linked acyl groups with hydroxylamine, then labels the newly exposed cysteines.
This can enrich candidate S-acylated proteins.
But chemistry-based enrichment needs controls because incomplete blocking or non-specific reactions can create false signals.
Stage 22: Acyl-RAC Uses a Related Capture Logic
Resin-assisted capture also converts thioester cleavage into selective enrichment of previously acylated cysteines.
It is powerful for proteome-scale discovery but still does not, by itself, identify the writer enzyme or turnover rate.
Stage 23: 17-ODYA Enables Metabolic Labelling
Cells can be supplied with an alkyne-containing fatty-acid analogue such as 17-ODYA.
After incorporation, click chemistry attaches a reporter for imaging or enrichment.
This directly tests incorporation of an acyl analogue into proteins.
Stage 24: Each Method Sees a Different Slice of Reality
Acyl-exchange methods are good at capturing thioester-linked sites.
Metabolic labelling is good at following incorporation.
Mass spectrometry can identify proteins and sites.
Microscopy gives spatial context.
No single method answers every question.
Stage 25: Inhibitors Can Mislead
Historically, 2-bromopalmitate has been widely used to perturb palmitoylation.
But it affects multiple lipid-handling enzymes and can also perturb deacylation pathways.
Therefore:
drug effect ≠ proof of one ZDHHC mechanism.
Genetics, site mutation and orthogonal chemistry are stronger when combined.
Stage 26: Cysteine Mutation Is Useful but Not Automatically Clean
Replacing a cysteine can abolish an acylation site.
But the same mutation can also change:
- protein folding;
- local charge;
- other modifications;
- partner binding.
A site mutant is evidence, not a complete mechanism by itself.
Stage 27: Writer Knockout Can Reveal Specificity
If removing one ZDHHC lowers substrate palmitoylation, that supports writer involvement.
Stronger evidence adds:
- rescue with wild-type enzyme;
- failure of catalytic-dead rescue;
- direct interaction or proximity;
- site-resolved measurement;
- receiver phenotype.
Stage 28: Depalmitoylase Perturbation Tests the Reverse Flux
If blocking ABHD17 or APT activity increases residence of a substrate at a membrane, that supports a dynamic cycle.
But substrate specificity must be demonstrated because many hydrolases have multiple targets.
Stage 29: Disease Variants Are Natural Mechanistic Experiments
Variants in ZDHHC enzymes, depalmitoylases or palmitoylated substrates can reveal which parts of the cycle are biologically important.
However, disease association does not prove that every phenotype arises only through palmitoylation.
Proteins often have additional functions.
Stage 30: Professional Palmitoylation Biology Is a Flux Problem
The professional question is:
Which cysteine on which substrate is acylated by which writer in which compartment, how quickly is the mark removed by which eraser, and which localisation or signalling change depends causally on that turnover?
Evidence: How We Know
Strong studies combine several layers:
- site-resolved mass spectrometry;
- acyl-biotin exchange or acyl-RAC;
- metabolic fatty-acid analogues;
- writer and eraser genetics;
- catalytic-dead rescue;
- live-cell localisation;
- protein half-life measurement;
- functional receiver assays.
Misconceptions Worth Hunting
- Palmitoylation is permanent.
- Every palmitoylated protein is a membrane protein.
- Every modified cysteine carries palmitate specifically.
- A ZDHHC enzyme recognises one simple consensus sequence.
- More palmitoylation always means more signalling.
- Depalmitoylation always turns a protein off.
- 2-bromopalmitate proves a specific ZDHHC pathway.
- A cysteine mutant proves the phenotype is caused only by lipidation.
- A palmitoyl-proteomics hit proves the site is functionally important.
Transfer Check
A protein becomes more palmitoylated after an ABHD17-family depalmitoylase is inhibited. Does that prove a ZDHHC enzyme became more active?
No. The same steady-state increase can arise because removal slowed.
A cysteine mutant loses plasma-membrane localisation. Does that prove the lipid itself was the only localisation signal?
No. The mutation could also disturb another interaction, and many proteins use multiple targeting cues.
Two cells have the same palmitoylation occupancy but different signalling. Is that possible?
Yes. Turnover rate, compartment, partner availability and membrane microdomain can differ.
How We Know the Learning Has Held
A learner should be able to explain the thioester bond, distinguish S-palmitoylation from irreversible lipidation, describe ZDHHC autoacylation and transfer, explain depalmitoylation, distinguish occupancy from turnover, compare biochemical and metabolic-labelling methods, and design a causal experiment that connects a lipidation site to a receiver-level phenotype.
Model Limits
“Palmitoylation” can hide acyl-chain diversity. Proteomics can miss low-occupancy sites. Hydroxylamine-based methods require careful controls. Metabolic analogues can differ from native fatty acids. ZDHHC redundancy can mask phenotypes. Disease studies may involve pleiotropic proteins. Current inhibitor selectivity is imperfect for many enzymes.
Professional reasoning keeps:
substrate + cysteine site + writer + acyl donor + compartment + eraser + turnover + receiver consequence
visible together.
Teaching Guide
Teach in this order:
cysteine chemistry → thioester → membrane affinity → ZDHHC autoacylation → substrate transfer → depalmitoylation → trafficking cycle → measurement → causal perturbation → disease and research limits.
Begin with:
If a protein needs to visit a membrane temporarily, what kind of chemical modification would be easier to regulate: a permanent anchor or a reversible one?
Connect This to the eduKate Science Estate
Research Foundations and Freshness Checks
- 2026 review: ZDHHC-mediated protein S-palmitoylation
- 2026 Biochemistry review: S-Palmitoylation in Health and Disease
- 17-ODYA metabolic labelling and palmitoyl-proteomics
- ABHD17 regulation of plasma-membrane palmitoylation
- ZDHHC substrate recruitment and regulatory structure
The Quiet Ending
The beginner asks, “Is this protein palmitoylated?”
The developing cell biologist asks, “Which enzyme writes and removes the mark?”
The advanced learner asks, “How does the cycle change membrane residency?”
And the professional asks:
What is the measured flux through this acylation cycle, where does it happen, and which biological output actually depends on that flux?
Science Hub Route
Continue through the eduKate Sengkang Science Hub · Complete Science Index
